Assessment of the level of fibrosising factors in patients with coronary heart disease and chronic kidney disease
Objective: to study the level of fibrosing factor in patients with coronary heart disease and chronic kidney disease.Materials and methods: the study included 115 patients, mean age was 67.56 ± 12.42 years (63 men and 52 women) with ischemic heart disease (CAD), stable angina (tension), functional class 1-3, chronic kidney disease (CKD) C1-C4. The level of serum fibroblast growth factor 23 (FGF 23) was assessed using a multimatrix enzyme immunoassay for the quantitative determination of FGF 23 (Biomedica FGF 23).Results: in patients with CAD and CKD, the level of serum FGF23 progressively increases as the stage of CKD worsens and can be regarded as an early marker of CKD progression in patients with CAD. When studying the correlation between the level of serum FGF 23 and clinical and laboratory data, it was found that there is a correlation between FGF 23 and age, creatinine, urea, glomerular filtration rate.Conclusion: in patients with CAD and CKD, it is advisable to use the determination of the level of fibrosis factors to identify patients with a high risk of cardiovascular complications.